MACK - Merrimack Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.10
-0.09 (-1.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.19
Open6.18
Bid5.00 x 1400
Ask0.00 x 3100
Day's Range6.05 - 6.43
52 Week Range3.34 - 10.53
Volume43,155
Avg. Volume77,841
Market Cap81.391M
Beta (3Y Monthly)2.57
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-05-30
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire6 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK

    Pomerantz LLP is investigating claims on behalf of investors of Merrimack Pharmaceuticals, Inc. (“Merrimack” or the “Company”) (NASDAQ: MACK).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On April 4, 2019, Merrimack announced the discontinuation of work on its sole drug candidate in clinical trials, MM-310, citing safety issues.  Despite amending the protocol for its Phase 1 study after observing and disclosing signs of peripheral neuropathy in clinical trial participants beginning in November, Merrimack reported that subjects taking MM-310 continued to experience weakness, numbness and extremity pain associated with peripheral neuropathy.  On this news, Merrimack’s stock price fell $1.18 per share, or 16.41%, to close at $6.01 per share on April 5, 2019.

  • ACCESSWIRE16 days ago

    Merrimack Pharmaceuticals, Inc. (MACK) - Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation

    NEW YORK, NY / ACCESSWIRE / April 8, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Merrimack Pharmaceuticals, Inc. (''Merrimack'' or the ''Company'') ...

  • PR Newswire20 days ago

    Merrimack Discontinues Development of MM-310

    CAMBRIDGE, Mass., April 4, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), an oncology company focused on biomarker-defined cancers, today announced the Company is discontinuing development of MM-310, its antibody-directed nanotherapeutic for the treatment of solid tumors. Based on emerging data since the recent amendment of the clinical protocol, the Company has concluded that the study would not be able to reach an optimal therapeutic index for MM-310.

  • PR Newswire2 months ago

    Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results

    CAMBRIDGE, Mass. , March 6, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its fourth quarter ...

  • GlobeNewswire2 months ago

    New Research: Key Drivers of Growth for ON Semiconductor, Entegris, Universal, MarineMax, Epizyme, and Merrimack Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire4 months ago

    John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman

    MORRISVILLE, N.C., Dec. 10, 2018 -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that John M. Dineen has.

  • GlobeNewswire5 months ago

    Research Report Identifies Merrimack Pharmaceuticals, PNM Resources, Inc. (Holding Co.), Carrols Restaurant Group, American Axle & Manufacturing, CBIZ, and Nova Measuring Instruments with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire6 months ago

    Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review

    - Company to initiate corporate restructuring, including ~60% reduction in force and significant reduction in operating expenses; potential to extend runway into at least 2H 2022 to preserve ability to ...

  • PR Newswire6 months ago

    Merrimack Announces Timing of Third Quarter 2018 Investor Conference Call

    The call will provide an update on Merrimack's pipeline, including the results of its portfolio review, as well as a summary of its third quarter 2018 financial results. A listen-only webcast of the call will be available in the Investors section of Merrimack's website, investors.merrimack.com, and a replay of the call will be archived there for six weeks. Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives.

  • PR Newswire6 months ago

    Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility

    CAMBRIDGE, Mass., Oct. 19, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the termination of the SHERLOC study, its randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive NSCLC. Based on these results, Merrimack is implementing a comprehensive review of its drug candidate pipeline, including assessing the impact of these results on the continued development of MM-121. MM-121 is also currently being evaluated in the SHERBOC study, a Phase 2 clinical trial evaluating MM-121 in combination with fulvestrant, versus fulvestrant alone, in patients with heregulin positive, hormone receptor positive, ErbB2 (HER2) negative, metastatic breast cancer.

  • PR Newswire7 months ago

    Merrimack Receives $5 Million Milestone Payment from Shire

    CAMBRIDGE, Mass., Sept. 20, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has received a $5 million milestone payment from Shire, triggered by the sale of ONIVYDE in the first major non-European, non-Asian country, pursuant to the terms of Merrimack's asset sale to Ipsen in 2017. "Since the start of the third quarter, Merrimack has received $38 million in non-dilutive capital, including two milestone payments from Shire totaling $23 million," said Richard Peters, M.D., Ph.D., President and Chief Executive Officer of Merrimack. The terms of the Company's asset sale to Ipsen in 2017 entitled Merrimack to receive up to an aggregate of $33.0 million in net milestone payments from Shire, of which Merrimack has now received $23.0 million, including this milestone and the $18.0 million payment in August 2018 resulting from the sale of ONIVYDE in two additional major European countries.

  • PR Newswire8 months ago

    Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)

    CAMBRIDGE, Mass., Sept. 6, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has completed enrollment in its ongoing SHERLOC study, a Phase 2 clinical trial evaluating its lead investigational drug candidate, MM-121, in patients with heregulin positive NSCLC. "We believe the robust clinical interest we have seen in the SHERLOC study reflects the significant unmet medical need among this patient population," said J. Marc Pipas, M.D., Merrimack's Senior Medical Director and Project Leader for MM-121. The SHERLOC study is a global, randomized, biomarker-selected, open-label Phase 2 clinical trial of MM-121 in combination with docetaxel, versus docetaxel alone, in patients with heregulin positive NSCLC.

  • PR Newswire9 months ago

    Merrimack Reports Second Quarter 2018 Financial Results

    - $18 million milestone payment received from Shire; Company continues to strengthen cash position from non-dilutive sources - - Two clinical readouts anticipated in 2018: randomized Phase 2 SHERLOC study ...

  • ACCESSWIRE9 months ago

    Merrimack Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 ...

  • PR Newswire9 months ago

    Merrimack Announces Timing of Second Quarter 2018 Investor Conference Call

    The call will provide an update on Merrimack's recent progress as well as a summary of its second quarter 2018 financial results. A listen-only webcast of the call will be available in the Investors section of Merrimack's website, investors.merrimack.com, and a replay of the call will be archived there for six weeks. Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives.

  • PR Newswire10 months ago

    Merrimack Secures $25 Million Debt Facility with Hercules Capital

    CAMBRIDGE, Mass., July 2, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the closing of a $25 million term loan with Hercules Capital (HTGC), $15 million of which was funded at closing today. Merrimack's current cash and cash equivalents, including the $15 million of loan proceeds received, and certain potential net milestone payments anticipated from Shire are projected to fund the company's planned operations into the first quarter of 2020. "This non-dilutive financing strengthens Merrimack's financial position, allowing us to remain focused on advancing the discovery, clinical and business development efforts for our nine wholly-owned programs in development, including our two clinical readouts expected later this year from MM-121 and MM-310," said Richard Peters, M.D., Ph.D., President and Chief Executive Officer of Merrimack.

  • PR Newswire10 months ago

    Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer

    - CARRIE study did not meet primary or secondary endpoints - - Company ceases development of MM-141 - - Focus remains on advancing Merrimack's promising clinical and preclinical pipeline, with two additional ...

  • PR Newswire11 months ago

    Merrimack to Present at the 2018 American Society of Clinical Oncology Annual Meeting

    CAMBRIDGE, Mass., May 29, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it will present two posters at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2018 at McCormick Place North/South in Chicago. A poster with an analysis of pharmacokinetic and safety data comparing different dosing regimens from nine previous Phase 1 and Phase 2 studies of seribantumab in solid tumors will be presented. Seribantumab is Merrimack's wholly-owned, fully human monoclonal antibody targeting HER3 (ErbB3).

  • PR Newswirelast year

    Merrimack Reports First Quarter 2018 Financial Results

    - Three clinical readouts expected in 2018, including data from two randomized Phase 2 studies - - Conference call at 8:30 am ET today - CAMBRIDGE, Mass. , May 8, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, ...